Jetema , a medical device and pharmaceutical manufacturing research company, is entering the filler market ahead of the registration of its botulinum toxin in China.
Jetema Shaghai, a subsidiary of Jetema, announced on the 17th that it has signed a distribution and promotion contract for the hyaluronic acid (HA) dermal filler 'eptq (hereinafter referred to as Epitique)' with Huadong Medical Aesthetics Biotechnology (Ningbo), a specialized aesthetic distribution corporation and Chinese botulinum toxin partner.
With this contract, Hwadong Aesthetics will be the official importer of Epitique and will have exclusive distribution and promotion for 5 years after launch. The total contract amount is 43.9 billion won (30.45 million dollars), and Jetema will establish a sales network for its main products, HA filler and botulinum toxin, in the Chinese market. China currently boasts a beauty market worth 8 trillion won and is rapidly emerging as a center of the global beauty industry.
Jetema expects to complete the Chinese approval for the product within the first half of this year. Based on this, it plans to proceed with sales in China based on the product purchase order (PO) confirmed by the partner company. The two companies are focusing on solidifying the distribution strategy according to the local market trend through continuous communication ahead of the product launch in the Chinese market.
Huadong Aesthetics, located in Huadong, Hangzhou, China, is an aesthetic distribution corporation established by key personnel of the existing Huadong Ningbo while maintaining distribution channels. In February 2022, it signed a botulinum toxin supply contract worth approximately KRW 600 billion with Jetema.
In the past, Huadong Ningbo was known as a beauty distribution company focusing on medical aesthetic distribution, as it ranked first in sales in the Chinese aesthetic market and signed an exclusive distribution contract with LG Life Sciences for filler products in China in 2013. The company explained that with these personnel joining Huadong Aesthetics in large numbers, there will be no problems at all in the future sales distribution network.
Jetema aims to generate over 40 billion won in Epitique sales in China alone through a five-year contract with Huadong Aesthetics. This contract is considered to be part of an important strategic decision that will further strengthen Jetema’s position in the global market.
A Jetema official said, “This contract is significant in that Jetema is establishing a corporation in China, a representative country among the world’s largest beauty markets, and is making a direct and full-scale entry into the market.” They continued, “While registering botulinum toxin in the Chinese market, we will widely promote the innovative brand Jetema there with the HA filler ‘Epitique’ that will be launched first, and we will produce excellent results that exceed expectations through synergy by combining our own marketing with the marketing know-how of a medical aesthetic distribution company that is the number one seller of beauty products in China.”
- See more related articles
You must be logged in to post a comment.